Revvity unveils pHSense reagents to accelerate targeted therapeutic development
Revvity has launched pHSense™ reagents, a breakthrough technology designed to advance internalization studies in drug discovery workflows. The innovative system targets researchers investigating G protein-coupled receptors (GPCRs) and antibody-drug conjugates (ADCs), offering enhanced accuracy and scalability for therapeutic development programmes.
Revolutionary detection capabilities
The pHSense platform combines pH-sensitive dyes with time-resolved fluorescence (TRF) readout technology, enabling robust kinetics analysis of internalization processes. This dual-component approach delivers exceptional signal-to-background ratios, maintaining sensitivity even at low endogenous receptor expression levels – a significant advancement for physio-logically relevant research conditions.
Developed for standard plate readers, the reagents integrate seamlessly with existing laboratory infrastructure whilst providing high-throughput capabilities essential for modern drug discovery pipelines. The technology demonstrates particular promise in addressing current limitations including suboptimal throughput and poor signal-to-noise ratios that have historically constrained internalization assays.
Addressing therapeutic development challenges
“pHSense reagents fill a critical gap in internalization assay technologies, directed towards enabling researchers to gain faster, more reliable insights using more physiologically relevant conditions,” said Craig Monell, senior vice president, reagents at Revvity. “With this launch, Revvity reinforces its commitment to advancing drug discovery through innovative tools that are focused on improving data quality, throughput, and reproducibility.”
Strategic positioning for precision medicine
The technology arrives as pharmaceutical research increasingly emphasises receptor tracking methodologies, particularly within oncology and precision medicine applications. ADC development represents a rapidly expanding therapeutic area where accurate internalization monitoring proves crucial for optimising drug efficacy and safety profiles.
By enabling more efficient screening and characterisation of promising therapeutic candidates, pHSense reagents can potentially accelerate preclinical development timelines whilst reducing overall development costs. This efficiency gain could contribute to faster advancement of candidates toward clinical evaluation stages.
The pHSense system maintains full compatibility with Revvity’s multimode detection platforms, ensuring streamlined integration into established drug discovery workflows without requiring substantial infrastructure modifications.
For more information, visit: www.revvity.com/reagents
Digital issue: Please click here for more information
